Journal of Cancer Research and Therapeutics Close
 

Figure 2: Clinical value of ATF7 in HER2-positive breast cancer patients. (a) HER2-positive breast cancer patients were divided into three groups based on tumor stage (Stage I, II, III, and IV). Subsequently, multiple comparisons between ATF7 expression and tumor stage were conducted using a one-way ANOVA and Tukey's test. *Stage I versus Stage II or Stage IIII; #Stage II versus Stage III; $Stage IV versus Stage III, (b) survival analysis was performed using Kaplan-Meier Plotter in HER2-positive breast cancer patients according to ATF7 expression status (low and high ATF7). *,#,$P < 0.05, **P < 0.01. ATF7 = Activating transcription factor 7, HER2 = Human epidermal growth factor receptor 2

Figure 2: Clinical value of <i>ATF7</i> in HER2-positive breast cancer patients. (a) HER2-positive breast cancer patients were divided into three groups based on tumor stage (Stage I, II, III, and IV). Subsequently, multiple comparisons between <i>ATF7</i> expression and tumor stage were conducted using a one-way ANOVA and Tukey's test. *Stage I versus Stage II or Stage IIII; <sup>#</sup>Stage II versus Stage III; <sup>$</sup>Stage IV versus Stage III, <b>(b)</b> survival analysis was performed using Kaplan-Meier Plotter in HER2-positive breast cancer patients according to <i>ATF7</i> expression status (low and high <i>ATF7</i>). *<sup>,#,$</sup><i>P</i> < 0.05, **<i>P</i> < 0.01. <i>ATF7 </i>= Activating transcription factor 7, HER2 = Human epidermal growth factor receptor 2